Brain metastasis as a primary manifestation of underlying disease

Yu.V. Dumanskyi, O.Yu. Stoliarova, O.V Syniachenko, Ye.D. Yehudina, F.A. Stepko


Background. The purpose of our work was to determine the incidence and nature of metastatic brain lesions in lung cancer (LC), correlation with other clinical signs of the disease (localization, shape, histology, degree of differentiation and staging of tumor, metastasis to other parts of the body), to identify the prognostic criteria of possible brain metastases (BM), to study the side effects of anticancer therapy and to evaluate the impact of BM on survival of the patients. Materials and methods. The study included 1,071 patients with lung cancer aged 24 to 86 years. None of the exa-mined patients had been operated previously for underlying disease, all patients received radiation therapy after establishment of the diagnosis, 3/4 of them underwent combined radiochemotherapy. Results. BM occur in 8 % of patients with LC (2.2 times more often in women) that is influenced by the peripheral form, histological variant (squamous and large cell carcinoma) and integrated severity of the tumor process, the presence of exudative malignant pleurisy, tumor invasion into the mediastinum and concomitant diabetes mellitus type 2. The severity of BM in lung cancer directly correlates with metastasis in the supraclavicular, inguinal and retroperitoneal lymph nodes, pericardium, adrenal glands, abdominal wall, liver and pancreas. The predictor of BM in patients with lung cancer may be elevated blood level of transforming growth factor β1, vascular endothelial growth factor and osteopontin. In 6 % of radiochemotherapy complications, there were detected acute cerebrovascular accidents of varying severity, which is closely associated with hypertension and diabetes, the form of LC, the number of metastases in the lymph nodes (but not in the brain) and with antitumor alky-lating agents used in comprehensive treatment. Conclusions. The so-called “brain form” of LC is characterized by greater severity, requires correction of drug chemotherapy, determines the survival of the patients that is lower in patients with BM.


cancer; lung; brain; metastases


Беляков К.М., Густов А.В. Паранеопластические полиневропатии. — Астрахань: Медицина, 2007. — 95 с.

Зайцев А.М., Куржупов М.И., Пикин О.В., Картовещенко А.С. Одномоментное хирургическое вмешательство при раке легкого с метастатическим поражением головного мозга // Онкология. — 2013. — № 5. — С. 49-52.

Евтушенко С.К. Паранеопластические неврологические синдромы: клиника, диагностика и возможности лечения // Международный неврологический журнал. — 2011. — № 8. — С. 5-15.

Бондарь Г.В., Думанский Ю.В., Попович А.Ю. Онкология. — К.: Медицина, 2015. — 576 с.

Ceniceros L., Aristu J., Castanon E. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients // Clin. Transl. Oncol. — 2015. — № 55(8). — Р. 213-9.

Chaari A., Ben Nasr S., Labidi S. Metastatic non-small cell lung cancer: a tunisian retrospective study about 100 cases // Tunis Med. — 2015. — № 93(5). — Р. 294-6.

Chen K.H., Wang K.J., Adrian A.M. Diagnosis of brain metastases from lung cancer using a modified electromagnetism like mechanism algorithm // J. Med. Syst. — 2016. — № 40(1). —

Р. 35-40.

D’Antonio C., Passaro A., Gori B. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies // Ther. Adv. Med. Oncol. — 2014. — № 6(3). — Р. 101-14.

Grаdalska-Lampart M., Karczmarek-Borowska B., Radziszewska A.U. Lung cancer in Podkarpackie region in the years 2002–2011 // Pneumonol. Alergol. Pol. — 2015. — № 83(2). —

Р. 109-19.

Hong N., Joo J.H., Shin S.H. The efficacy of postoperative chemotherapy for patients with metastatic brain tumors from non-small cell lung cancer // Brain Tumor Res. Treat. — 2015. — № 3(2). —

Р. 108-14.

Kang C.G., Han H.J., Lee H.J. Rho-associated kinase signa­ling is required for osteopontin-induced cell invasion through inactiva­ting cofilin in human non-small cell lung cancer cell lines // Bioorg. Med. Chem. Lett. — 2015. — № 25(9). — Р. 1956-60.

Kawashima M., Murakawa T., Shinozaki T. Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery // Interact. Cardiovasc. Thorac. Surg. — 2015. — № 12(8). — Р. 115-25.

Kukulj S., Popovic F., Budimir B. Smoking behaviors and lung cancer epidemiology: a cohort study // Psychiatr. Danub. — 2014. — № 26(3). — Р. 485-9.

Lin Q., Guo L., Lin G. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer // Cancer Epidemiol. — 2015. — № 39(4). — Р. 539-44.

Munoz-Esquerre M., Huertas D., Escobar I. Gene and protein expression of fibronectin and tenascin-c in lung samples from COPD patients // Lung. — 2015. — № 193(3). — Р. 335-43.

Oh J.H., Craft J.M., Townsend R. A bioinformatics approach for biomarker identification in radiation-induced lung inflammation from limited proteomics data // J. Proteome Res. — 2011. — № 10(3). — Р. 1406-15.

Qu H.M., Bai Y.N., Cheng N. Trend analysis of cancer mortality in the jinchang cohort, China, 2001–2010 // Biomed. Environ. Sci. — 2015. — 28(5). — Р. 364-9.

Rong J., Chunhua M., Yuan L. Clinical interrogation and application of super-selective intracranial artery infusion chemotherapy for lung cancer patients with brain metastases // Indian J. Cancer. — 2015. — 52(Suppl.). — Р. 22-5.

Takei H., Rouah E., Ishida Y. Brain metastasis: clinical cha-racteristics, pathological findings and molecular subtyping for therapeutic implications // Brain Tumor. Pathol. — 2015. — № 3(10). — Р. 140-5.

Waqar S.N., Waqar S.H., Trinkaus K. Brain metastases at presentation in patients with non-small cell lung cancer // Am. J. Clin. Oncol. — 2015. — № 33(10). — Р. 167-75.

Zegers C.M., Rekers N.H. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects // Clin. Cancer Res. — 2015. — № 21(5). — Р. 1151-60.

Zhou T., Zhan J., Hong S. Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer // Sci. Rep. — 2015. — № 18(5). — Р. 10481.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта